The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...
Seborrheic dermatitis is linked to other epithelial barrier diseases, supporting the epithelial barrier theory as a shared ...
NDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based on positive data from the ...
Mischief-makers can guess the subjects being discussed with LLMs using a side-channel attack, according to Microsoft ...
allAfrica.com on MSN
South Africa and Indonesia Team Up On Massive Asymptomatic TB Study
Over the last decade, there's been growing evidence that people can have TB without having any symptoms. But there is still much uncertainty over how such asymptomatic TB functions in the body and how ...
In a study of more than 100,000 screening mammograms, researchers demonstrated the potential of an AI tool to help identify women at higher risk of developing interval breast cancers, breast cancer ...
Based on the DESTINY-Breast06 phase III trial results demonstrating statistically significant and clinically meaningful progression-free survival benefit in patients treated with Enhertu vs.
Delivered Q3 2025 revenue of $83 millionQ32025 non-dermatologic revenue increased by 67% over Q32024Q32025 total test reports ...
Q3 2025 Earnings Call November 7, 2025 11:00 AM ESTCompany ParticipantsAl Petrie - Officer of Investor RelationsPaul McKinney - ...
Introduction Adolescence is a key period of development for mental health; however, little is known about how (cumulative) daily life experiences impact long-term mental health development in this ...
Tecogen Inc. (NYSE American:TGEN), a leading manufacturer of clean energy products, reported revenues of $7.18 million and net loss of $2.13 million for the quarter ended September 30, 2025 compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback